Latest Safety News

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its PYC-003 clinical trial and will soon begin dosing patients with Polycystic Kidney Disease, marking a pivotal step forward.

Nanosonics has launched trophon3, its next-generation ultrasound disinfection device, alongside a software upgrade for existing users, promising faster cycles and enhanced digital integration.

Dynamic Metals has secured heritage and regulatory approvals to commence a targeted 13-hole drilling program at its Chalice South gold prospect, advancing exploration in a proven mineralised corridor in Western Australia.

3D Energi Limited confirms final well locations and a September 2025 start for Phase 1 of its Otway Basin drilling program, with ConocoPhillips covering up to US$65 million of costs.

Pure Hydrogen Corporation has secured a 48-month distribution agreement with Argentina's FRN Enterprise to advance hydrogen and electric vehicle sales across South America, targeting US$20 million in revenue.

RocketDNA has secured an 18-month contract with Vault Minerals to provide advanced aerial data services at the King of the Hills gold operation, integrating its latest autonomous drone technology and automated data processing.

First Graphene Limited is progressing two major projects in hydrogen storage and aerospace 3D printing, backed by multi-million-dollar UK grants to commercialise graphene-enhanced technologies.

Horseshoe Metals has secured crucial Direct Shipping Ore mining approval for its Horseshoe Lights Copper-Gold Project, setting the stage for imminent production and early revenue generation from high-grade copper stockpiles.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

HMC Capital has delayed the Neoen VIC Portfolio acquisition settlement by one month, secured a $200 million mezzanine financing facility, and announced a strategic merger of its renewable energy platforms under new leadership.